disease interaction(s) of diabetes mellitus type 2 with myocardial infarction
Jump to navigation
Jump to search
Management
- colchicine 0.5 mg QD initiated within 30 days after a myocardial infarction in patients with diabetes mellitus type 2 reduces risk of cardiovascular events (RR=0.65)
* nausea & pneumonia more common with colchine than placebo (absolute risk < 3%)
More general terms
References
- ↑ Roubille F, Bouabdallaoui N, Kouz S, et al. Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024 Jan 5:dc231825 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38181203